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Abstract 
Background: the parasympathetic nervous system (PNS), via neurotransmitter 
Acetylcholine (ACh), modulates fibrogenesis in animal models. However, the role of ACh in 
human hepatic fibrogenesis is unclear. Aims: we aimed to determine the fibrogenic responses 
of human hepatic stellate cells (hHSC) to ACh and the relevance of the PNS in hepatic 
fibrosis in patients with non-alcoholic steatohepatitis (NASH). Methods: primary hHSC were 
analysed for synthesis of endogenous ACh and acetylcholinesterase (AChE), and gene 
expression of choline acetyltransferase (ChAT) and muscarinic acetylcholine receptors 
(mAChR). Cell proliferation and fibrogenic markers were analysed in hHSC exposed to ACh, 
Atropine (Atrop), Mecamylamine (Mec), methoctramine and 4-Diphenylacetoxy-N-
methylpiperidine methiodide (4-DAMP).  MAChR expression was analysed in human NASH 
scored for fibrosis. Results: we observed that hHSC synthesise ACh and AChE, and express 
ChAT and M1-M5 mAChR. We also show that M2 was increased during NASH progression, 
while both M2 and M3 were found upregulated in activated hHSC. Furthermore, endogenous 
ACh is required for hHSC basal growth. Exogenous ACh resulted in hHSC 
hyperproliferation via mAChR and PI-3K and MEK signalling pathways, as well as increased 
fibrogenic markers. Conclusion: We show that ACh regulates hHSC activation via M2 and 
M3 mAChR involving the PI-3K and MEK pathways in vitro. Finally, we provide evidence 
that the PNS may be involved in human NASH fibrosis.  
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Introduction 
It is well established that hepatic stellate cells (HSC) are the principal fibrogenic cell type of 
the liver. Following injury, inflammatory cytokines convert the quiescent HSCs into activated 
HSC, which are highly proliferative and exhibit increased collagen type-1 and α-smooth 
muscle actin (ASMA) deposition, culminating in ECM accumulation and fibrosis
1
. Hepatic 
fibrosis is the end stage of many chronic liver diseases, with non-alcoholic fatty liver disease 
(NAFLD) the most common form of chronic liver disease in the Western world
2, 3
. NAFLD is 
an infiltration of fat into the parenchyma of the liver, which is tightly related to obesity, 
insulin resistance, metabolic syndrome and aging
4-7
. Ongoing inflammation and impaired 
wound healing responses progress NAFLD to the more severe disease non-alcoholic 
steatohepatitis (NASH)
8, 9
, which may in turn progress to advanced fibrosis, cirrhosis and 
end-stage liver disease
10, 11
. The mechanisms underlying this progression to cirrhosis are 
currently unclear. Recent evidence suggests the parasympathetic nervous system (PNS) plays 
a role in the regulation of cell proliferation and wound healing involved in fibrogenic 
pathologies of the skin and airway epithelial cells
12, 13
. The cholinergic pathway also has 
implications in modulating inflammation in multiple disease states including atopic 
dermatitis, and cystic fibrosis
14, 15
. Further evidence also suggests dietary fat modulates 
inflammatory processes via the cholinergic pathway
16-19
, showing the PNS may be implicated 
in obesity and associated metabolic disorders such as NAFLD. 
The PNS has also been implicated in murine hepatic fibrogenesis. In the carbon tetrachloride 
(CCl4) murine model of liver injury, AChE positive nerve fibres are shown to occur in the 
fibrous septa of cirrhotic rat livers and these fibres form nerve terminal/myofibroblast 
complexes
20
. Furthermore, results from our group show that murine hepatic stellate cells 
(mHSC) are highly proliferative and have increased COL1A2 expression in response to 
exogenous acetylcholine, as well as nicotine
21, 22
. Concurrently, it was recently demonstrated 
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that culture activated mHSC express mAChR
22
. Other in vivo studies showed that cholinergic 
denervation reduces mHSC activation and proliferation in CCl4 induced liver fibrosis in 
rats
23
. Similar findings have also been suggested in humans, though results are conflicting
24
. 
These studies suggest a potential role for the PNS in regulating human hepatic fibrogenesis, 
particularly in the setting of NASH fibrosis, and further investigations are warranted. The aim 
of this study was to determine whether hHSC express mAChR, respond in a fibrogenic 
manner to acetylcholine and to determine the relevance of the PNS in hepatic fibrosis in 
patients diagnosed with NASH. 
 
Methods 
Human Hepatic Stellate Cell Isolation and Treatment 
Human liver tissue was acquired with approval by the appropriate local Ethical Committee 
and patient consent. Cell separation was conducted via collagenase and DNase perfusion
25
. 
Non-parenchymal cells including HSC were subsequently isolated
26
. Cells were plated at a 
density of 5x10
4
 cm
2
 in RPMI medium containing penicillin 100 u/mL and streptomycin 100 
µg/mL (Gibco, Invitrogen, UK), 10% Foetal Bovine Serum (FBS) (Gibco, Invitrogen, UK) 
and 2-ME (Gibco, Invitrogen, UK), and cultured to activation to day 15 on uncoated plastic 
flasks. Cell identity was confirmed by autofluorescence, and the expression of two well-
accepted HSC markers, alpha smooth muscle actin (AMSA) and glial fibrillary acidic protein 
(GFAP) by immunocytochemistry. When required, activated cells were exposed to drug 
treatment (Table 1).  
 
Acetylcholine and Acetylcholinesterase Activity Assay 
Activated hHSC were plated at a density of 5000 cells per well in a 96 well plate in RPMI as 
described above without 2-ME. Cell supernatant was collected after 48hours and 
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acetylcholine was measured using Amplex Red Acetylcholine/Acetylcholinesterase Assay 
Kit (Invitrogen, UK). Cells were trypsinized and counted using a NucleoCounter. Cells were 
also plated out as above, sonicated and centrifuged at 13,000 rpm for 20 minutes at 4°C and 
the supernatant collected. Acetylcholinesterase was measured in the sonicated cell 
supernatant using the same assay kit, since AChE is contained within the cell cytoplasm
27
. 
Fluorescence was measured in a fluorescence microplate reader (Anthos HT III) at excitation 
530-560 nm and emission 590 nm, and readings read off standard curve minus controls. 
Acetylcholine and acetylcholinesterase levels were measured as a ratio of cell numbers. 
 
Cell Proliferation Assay 
Activated hHSC were plated at a density of 5000 cells per well in a 96 well plate in RPMI 
containing 10% FBS. Cholinergic agonists and antagonists from Table 1 were added to the 
medium for 48hours. Cell proliferation assay was conducted as per protocol using WST-8 
cell counting kit (Dojindo Molecular Technologies, NBS Biologicals, UK). Optical densities 
were read with an Emax precision microplate reader (Anthos HT III) at 450nm. 
 
Apoptosis assay 
Activated hHSC were plated at a density of 1x10
6
 cells per T25 flask. Activated cells were 
exposed to cholinergic agonists and antagonists from Table 1 in RPMI containing 10% FBS 
for 48hours. Cells were lightly trypsinized and an apoptotic activity was performed with the 
Vybrant (annexin V) apoptosis assay kit 2 (Molecular Probes, Invitrogen) as per the 
manufacturer’s instructions. FACS analysis was performed using FACS Calibur.  
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RNA Isolation and RT-PCR 
Isolation of total RNA from cells and homogenised liver tissue was performed using 
TRIzol
TM
 Reagent (Invitrogen, UK) as per manufacturer’s instructions as previously 
performed
28
. Primers were designed using Primer3 (see Table 2). RNA from samples was 
reversed transcribed and amplified via PCR using Superscript III One-Step RT-PCR System 
(Invitrogen, UK) and SYBR Green
ER
 (Invitrogen, UK). Reactions were performed on 
Rotorgene thermal cycler (Rotorgene RG 3000, Corbett Research, Australia). cDNA was 
amplified (denaturation at 94°C for 15 sec, annealing temperatures as shown in Table 2 for 30 
sec, extension at 72°C for 60 sec). A melt curve analysis (50–90°C with a heating rate of 1° 
per second) confirmed the amplification of specific PCR products and the absence of non-
specific amplification or primer-dimers. The amount of transcript was calculated and 
expressed as the difference relative to the control gene GAPDH (2
-∆∆Ct
, where Ct represents 
the difference in threshold cycles between the target and control genes).  
 
Immunocytochemistry 
Immunocytochemistry was performed on activated hHSC. Cells were plated on sterilized 
cover slips at a density of 5x10
3
 cells per well of a 24well plate (Nunc, Thermo Fisher 
Scientific, UK) in RPMI media and grown to 50% confluence. Cells were washed with 
chilled PBS and fixed with methanol-acetone (50/50 v/v). The fixed cells were washed in a 
blocking solution containing 10% goat serum (Gibco, Invitrogen, UK) and 0.3% BSA (10% 
in DPBS) in PBS for 1hr at room temperature. Primary antibody diluted in block buffer was 
added for 1hr at room temperature. Final antibody dilution was anti-ASMA 1:400 (Santa 
Cruz, CA, US) and ChAT 1:100. Secondary antibodies conjugated to FITC and Texas Red 
were diluted in block buffer at 1:5000 and applied to cells for 1hr at room temperature. Slides 
  
This article is protected by copyright. All rights reserved. 
were mounted in VectraShield with DAPI (Vector Laboratories) on cover slips and examined 
with a Zeiss LSM 510 Meta Confocal Microscope
29
. 
 
MAChR expression in NASH fibrosis  
Whole liver NASH samples were supplied from the Laboratory of Morphology and 
Molecular pathology of the University of Leuven (Belgium) following the local Ethics 
Committee approval in accordance with the Helsinki Declaration. Written and informed 
consent was obtained for all participants. Right lobule liver biopsies were conducted and 
histologically scored for NASH on the Brunt fat content scaling system (n=3), confirming 
NASH, as well as scored for fibrosis on the METAVIR fibrosis score system
30
. The biopsies 
were snap frozen in liquid nitrogen and stored at -80°C. MAChR expression was analysed in 
these samples via RT-PCR. 
 
 
 
Statistical Analysis 
All experiments were performed in duplicate from 3 separate experiments and analysed using 
statistical program GraphPad Prism 6 (GraphPad Prism, San Diego, USA). Statistical 
significance was calculated using the Mann-Whitney t-test and a p value of <0.05 was 
considered significant (*) a p value of <0.01 considered highly significant (**) and a p value 
of <0.001 considered very highly significant (***). Results are represented as means ± SEM. 
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Results 
Human HSC express ChAT, and synthesise ACh and AChE, require ACh as an endogenous 
growth factor 
Until now, there was no data demonstrating the potential for hHSC to express and synthesise 
the cholinergic enzymes, ChAT, ACh and AChE. Here, we were able to demonstrate via 
confocal microscopy, that activated HSC cells expressed ChAT protein, found to be located 
in bundles and spread diffusely within the cell cytoplasm (Texas Red fluorescence), where 
ASMA (FITC), which is expressed abundantly, is used as a control protein to confirm the cell 
type and activated phenotype (Fig. 1A). We further demonstrated that activated hHSC 
cultured for 48 hours, release ACh at 25uM per 1x10
6
 cells or 0.25pM per cell into cell 
culture supernatant. hHSC with cytoplasmic AChE, were sonicated and the supernatant 
analysed for AChE. Enzyme assay found hHSC to release cytoplasmic AChE at a 
concentration of 180mU/mL per 1x10
6
 cells (Fig. 1B). Since hHSC synthesize acetylcholine 
and express acetylcholine receptors, we next determined whether the cells respond 
functionally to endogenous ACh. Cells cultured for 48hours with mAChR antagonist atropine 
(Atr 10uM), show basal cell growth inhibition (20% +/- 7%) as determined by proliferation 
assay, almost to the same extend as the cells cultured in serum free conditions (Fig. 1C).  
 
Activated hHSC express acetylcholine receptor mRNAs and protein 
Real time qPCR was performed to characterize cholinergic gene expression in activated 
hepatic stellate cells as well as whole liver and hepatocytes. It was found that activated 
human stellate cells express genes for all mAChR including mRNA for M2 > M3 > M1 > M4 
> M5 (Fig. 2A). HHSC expressed predominantly M2 and M3 muscarinic ACh receptors (Fig. 
2A). To confirm that M receptors expression in hHSC was not variable between human 
donors, expression of the ACh receptors was confirmed in 3 sets of isolated cells, and 
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although slight variability in receptor expression occurred between cells, these were not 
significant (data not shown). Human hepatocytes expressed mRNA for all mAChR with 
M3=M2 > M1=M4=M5, while whole liver scored with F4 fibrosis expressed all mRNA 
mAChR with M2 > M3 > M1 > M5 > M4 (Fig 2A). To confirm the expression at a protein 
level, M3 protein expression was analysed via immunofluorescence and confocal 
microscopy. Confocal microscopy of activated HSC showed the cells express M3 mAChR 
protein (Texas Red fluorescence) located in bundles, which may be consistent with a 
localisation in the Golgi apparatus in the perinuclear region of the cell cytoplasm, with 
ASMA (FITC) as a control for activated HSC phenotype (Fig. 2B).  
 
Acetylcholine stimulates hHSC proliferation via cell surface M2 and M3 (Gαq/11 protein) 
mAChR  
To assess the functionality of the cholinergic receptors, cells were cultured with various 
concentrations of ACh +/- atropine and cell proliferation was measured. Exogenous 
acetylcholine applied to cells was found to induce hHSC proliferation in a dose dependent 
manner with peak proliferation at 10nM-1uM (Fig. 3A). At 1uM, proliferation was increased 
to 140% +/- 2% of the FBS control. ACh at a dose of 1uM, which induced hHSC 
proliferation, was blocked by 10uM Atr to 90.7% +/-8% of FBS control (Fig. 3B), although 
this did not inhibit growth below the negative control (serum free). Since hHSC responded to 
acetylcholine with increased proliferation, an apoptosis assay was conducted to determine the 
effects of exogenous ACh on hHSC apoptosis. Human HSC exposed to ACh 1uM showed 
decreased stellate cell apoptosis by 21% +/- 2.8%. This effect was blocked when ACh 1uM 
and Atr 10uM were applied simultaneously (Fig. 3C). This further confirms that ACh not 
only directly increased cell survival, but also inhibited the normal programmed cell death of 
the stellate cells resulting in increased survival of the cells. The high expression of M2 and 
  
This article is protected by copyright. All rights reserved. 
M3 mAChR in activated hHSC as well as the increase in receptor expression in fibrotic liver 
suggests that these receptors may be directly involved with fibrogenesis. Due to hHSC 
endogenous Ach activity, atropine could inhibit Ach and increase the apoptotic stage. 
Surprisingly, we found a lack of effect of supplied Atr on endogenous Ach (Figure 3C), 
possibly related to cellular membrane permeability to Atropine or intracellular active Ach 
concentration. As acetylcholine supplementation triggered hHSC proliferation (Figure 3A 
and 3B), we focused our attention in this extra Ach role, rather than in the internal basal 
concentration. Therefore, we conducted further experiments to determine if blocking these 
specific receptors could inhibit ACh induced proliferation and collagen gene expression. 
Cells were exposed to ACh 1 uM as well as the M2 mAChR antagonist methoctramine, 
which antagonises the receptors at pM to nM concentrations, as well as M3 mAChR 
antagonist 4-DAMP. Here, we show that both methoctramine and 4-DAMP inhibit ACh 
induced proliferation from 140 +/- 2% to 95 +/- 20% and 98 +/-18% (Fig. 3D) respectively of 
the % response to FBS control.  
 
Acetylcholine stimulates hHSC proliferation via intracellular activation of the PI-3 kinase 
and MEK cell survival pathways 
To further characterise the intracellular mechanism by which hHSC proliferation occurs, cells 
were exposed to cell survival pathway inhibitors in the presence of ACh. Hepatic stellate 
cells were exposed to ACh 1uM, as well as antagonists for Gαi/o-protein (PT), PI3-kinase 
(WT), MEK (PD), p38MAP-kinase (SB), and PKC (RO). We found that blocking both the 
PI3-K and MEK cell survival pathways, resulted in inhibited ACh induced proliferation by 35 
+/- 5% and 42 +/- 4% respectively, suggesting ACh induced proliferation primarily occurs 
via PI3-K and MEK, though PKC antagonist also had a slight response inhibiting 
proliferation 20 +/- 8% (Fig. 4). The results obtained suggested the involvement of the Gαi/o-
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protein couple receptor antagonist pertussis toxin. In this respect, M2 and M4 are Gio 
proteins, while M1, M3 and M5 are Gαq/11-protein receptors. Thus, the lack of effect of PT 
on Ach-induced hHSC proliferation (Fig. 4) could suggest no M2 or M4 involvement in this 
process. However, this result should be considered with some caution, as our findings 
highlight the importance of M2 in hHSC proliferation and as there are other multiple 
potential Gio targets for PT (ie. adrenergic, cannabinoid, glutamate or serotonin receptors 
among others).   
 
Acetylcholine Induces hHSC TGF-B and Collagen Fibrogenesis via M2 and M3 mAChR 
hHSC induced fibrogenesis involves both cell proliferation and overproduction of matrix 
proteins including collagens. Here, we analysed the effects of ACh exposure on the 
production of matrix proteins. The conical pathway of collagen production occurs via TGF-B. 
To determine whether ACh alters collagen production, cells were exposed to ACh and 
analysed for changes in TGF-B and COL1A2 expression. TGF-B gene expression was 
significantly upregulated in ACh 1M treated cells to 200% +/- 23.4% of the FBS control 
(Fig. 5A), as was COL1A2 to 208% +/- 8.8% (Fig. 5B). COL1A2 expression was also 
inhibited by methoctramine and 4-DAMP from 208% +/- 8.8% to 170 +/- 9% and 173 +/- 
21% of the FBS control (Fig. 5C). 
 
 
M2 Ach receptor is upregulated in hHSC activation and in NASH fibrosis 
As our data suggested the importance of M2 and M3 mAChR expression and function in 
hHSC proliferation and fibrogenesis, we analysed their expression levels at the stage of 
activation of hHSC, from quiescent to activated phenotypes. It is already known that ASMA 
gene expression increases in cell activation from cells cultured from day 0 to day 15, a 
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defining characteristic of the cell type. Here, we demonstrated that M2 and M3 mAChR 
receptor expression increases in isolated hHSC (Fig. 6A). With these results, we next 
attempted to clarify the expression pattern of mAChR in vivo. Using whole liver biopsy 
samples from patients diagnosed with NASH and scored for fibrosis using the METAVIR 
fibrosis scoring system, we further demonstrated that as the fibrosis score rose from F0 to F4, 
ASMA gene expression which was used to confirm fibrosis of the samples increased 
significantly, as did M2 receptor gene expression, which significantly increased from 38% +/- 
12% in F0 samples to 250% +/- 48% in the F4 samples compared to GAPDH (Fig. 6B). 
Interestingly, M3 receptor expression remained unchanged between F0, F3 and F4, although 
expression levels in all samples were high at 303-398% (data not shown). 
  
Discussion 
This paper demonstrates via multiple techniques the importance of acetylcholine in regulating 
human hepatic stellate cell growth and activation. For the first time, we show that cultured 
hHSC produce ChAT and AChE, as well as secreting ACh, and that basal cell growth was 
inhibited when cultured with atropine. This demonstrates the ability of hHSC to produce and 
respond to endogenous acetylcholine, suggesting acetylcholine is an autocrine growth factor 
for hepatic stellate cells. To characterise these cells further, we showed that isolated hHSC 
express receptors of the PNS including mAChR M2 > M3 > M1 > M4 > M5. This is similar 
to the expression pattern seen in a recent publication of a murine model of hepatic fibrosis 
with HSC expressing M2>M3 mAChR. This expression pattern has also been reported in 
other human cell types with fibrogenic potential, including human lung fibroblasts and 
human scleral fibroblasts
31, 32
, suggesting that collectively, the role of the PNS in fibroblast 
regulation is likely to be significant. We also demonstrated that gene expression of M2 and 
M3 were upregulated with activation of hHSC, suggesting that they play an important role in 
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hepatic fibrogenesis. In addition, M2 expression increased in parallel with NASH progression 
in human biopsies. 
We further demonstrated that cell exposure to exogenous ACh induced hyper-proliferation of 
hHSC above that of basal cell growth as well as upregulating fibrotic markers TGF-B and 
COL1A2 gene expression. It appears that this process occurs via ACh binding M2 and M3 
mAChR, since blocking these receptors with methoctramine and 4-DAMP inhibited cell 
proliferation and reduced fibrotic markers to near control levels. These results are also 
consistent with others findings showing that murine HSC in vitro responds in a proliferative 
manner to ACh via M2 mAChR pathways
33
. This would suggest that ACh binding to M2 and 
M3 receptors in particular may be what stimulates the conversion of quiescent HSC into 
fibroblast phenotypes. Surprisingly, we detect M3 in bundles, indicating a possible 
localisation in the Golgi apparatus in the perinuclear region of the cell cytoplasm. In this 
regard, upon folding in the endoplasmic reticulum, proteins are driven to Golgi for 
maturation and later mobilization to their final functional locations. Furthermore, Golgi 
secretion granules could be fused with the external membrane. In neurons, although 
muscarinic receptors are usually located in cell surface, it has been described a cholinergic-
induced subcellular redistribution of muscarinic receptors to endoplasmic reticulum and 
Golgi complex
34
. 
We also found that ACh induced proliferation occurs via the intracellular signalling pathways 
involving PI-3K, MEK and PKC. Interestingly, this pathway of fibrogenesis is similar to that 
demonstrated in muscarinic induced human lung fibroblast proliferation in airway 
remodelling
35
, as well as other conditions of cellular hyper-proliferation, including a 
multitude of solid tumours such as HCC
36-38
. This pathway may be a significant therapeutic 
target in hepatic fibrogenesis and therefore, warrants further investigation. 
  
This article is protected by copyright. All rights reserved. 
 In human whole liver samples of NASH fibrosis, our results showed that M2 receptor 
expression was increased with severity of fibrosis. This suggests in vivo, that M2 may be 
involved in fibroblastic changes in NASH, particularly since HSC are the predominant cells 
causing hepatic fibrosis, and we have also shown in vitro that hHSC express M2. It is 
important to point out that the implications of altered PNS signalling in the liver is highly 
relevant, since dietary fat directly stimulates the cholinergic anti-inflammatory pathway via 
the vagal nerve
18, 19
, suggesting a plausible link between a high fat diet, the cholinergic 
system and fibrosis in NASH. This theory may also be relevant in the setting of progression 
to fibrosis post-liver transplantation where PNS innervation is permanently severed.  
In summary, cholinergic transmission in the liver is a novel explanation for the development 
of hepatic fibrogenesis. Our findings suggest pathological implications for ACh induced 
fibrogenesis via mAChR in primary human HSC and as well as in human NASH, and may be 
a potential therapeutic target.  
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Fig. 1. Hepatic stellate cells express choline acetyltrasferase (ChAT), and secrete 
acetylcholine (ACh) and acetylcholinesterase (AChE), and require ACh as an endogenous 
growth factor. (A) Immunocytochemistry showing activated hHSC express ASMA (FITC) 
and ACh synthesising enzyme ChAT (Texas Red) (scale line 10μM). (B) Activated hHSC 
synthesise and release ACh and AChE. ACh is required for hHSC basal cell growth. (C) Atr 
10uM inhibited hHSC basal growth 20% +/- 7% compare to FBS control. Experiments were 
performed in duplicate from 3 separate experiments. *: p < 0.05. 
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Fig. 2. hHSC, hepatocytes and whole liver express all mAChR. (A) Day 15 activated hHSC 
express M2 > M3 > M1 > M4 > M5 mRNA. While hepatocytes express mRNA for M3=M2 
> M1=M4=M5 and whole liver with F4 fibrosis express mRNAs M2 > M3 > M1 > M5 > 
M4. Samples were amplified by real time-PCR and electrophoresis performed on 1.5% 
agarose gel, 90V, 60 mins. hHSC results were also expressed as bar graphs. (B) Confocal 
microscopy of activated HSC showed the cells express M3 mAChR protein (Texas Red 
fluorescence) with ASMA (FITC) proving activated HSC phenotype (scale line 10μM). 
Experiments were performed in duplicate from 3 separate experiments. 
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Fig. 3. Acetylcholine stimulates hHSC proliferation upstream via M2 and M3 (Gαq/11 protein) 
mAChR, compared to FBS stimulated experimental group. (A) ACh 1uM induced hHSC 
proliferation in a dose dependent manner, with peak proliferation occurring at 10nM – 1uM 
increased to 140% +/- 2% of the FBS control. (B) ACh 1uM induced hHSC proliferation was 
blocked by Atr 10uM to 90.7% +/-8% of FBS control. (C) Human HSC exposed to ACh 1uM 
showed decreased stellate cell apoptosis by 21% +/- 2.8% when compared to FBS group. 
This effect was blocked when ACh 1uM and Atr 10uM were applied simultaneously. (D) 
Methoctramine inhibited ACh 1uM induced proliferation from 140 +/- 2% to 95 +/- 20% of 
FBS control while 4-DAMP inhibited ACh induced proliferation to 98 +/-18% of FBS 
control. Experiments were performed in duplicate from 3 separate experiments. *: p < 0.05 ; 
**: p < 0.01. 
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Fig. 4. hHSC exposed to ACh 1 µM as well as antagonist to Gαi/o-protein, PI3-kinase, MEK, 
p38MAP-kinase, and PKC showed that both the PI3-K and MEK antagonists (WT and PD) 
inhibited Ach 1 µM induced proliferation by 35 +/- 5% and 42 +/- 4%. Proliferation was also 
inhibited by PKC antagonist (RO) 20 +/- 8%). Experiments were performed in duplicate from 
3 separate experiments. *: p < 0.05 ; **: p < 0.01. 
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Fig. 5. ACh stimulation during 48 hours increased expression of fibrotic markers TGF-β and 
COL1A2 in hHSC, which is inhibited by 24 hours incubation together with M2 and M3 
AChR antagonists. (A) hHSC exposed to ACh 100nM and 1uM had increased TGF-β gene 
expression up to 200% +/- 23.4% of the FBS control. (B) COL1A2 gene expression increased 
to 208% +/- 8.8% of the FBS control. (C) This effect was reduced by Methoctramine and 4-
DAMP from 208% +/- 8.8% to 170 +/- 9% and 173 +/- 21% of the FBS control. Expression 
was determined by real time RT PCR and samples were standardised to GAPDH. 
Experiments were performed in duplicate from 3 separate experiments. (*: p < 0.05 ; **: p < 
0.01). 
  
This article is protected by copyright. All rights reserved. 
 
 
Fig. 6. M2 is upregulated in hHSC as well as in NASH fibrosis. (A) Isolated RNA from 
primary hHSC shows mRNAs for ASMA increased with cell activation time as did mRNAs 
for M2 and M3 AChR. (B) Whole liver biopsy samples from patients diagnosed with NASH 
and scored for fibrosis using the METAVIR fibrosis scoring system were analysed for 
ASMA, M2 and M3 mAChR. M2 expression increased from 38% +/- 12% in F0 samples to 
250% +/- 48% in the F4 samples. Experiments were performed in duplicate from 3 separate 
experiments. **: p < 0.01 ; ***: p < 0.001. 
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Table 1.  hHSC Drug Treatment  
Drugs Target and Action Concentration 
Acetylcholine (ACh) muscarinic and nicotinic AChR agonist 1nM – 1mM 
Atropine (Atr) muscarinic AChR antagonist 10M 
Pertussis Toxin (PT) inhibitor of Gαi/o-proteins 100ng/mL 
Wortmannin (WT) inhibitor of PI3-K 100nM 
PD 98059 (PD) inhibitor of MEK 20M 
SB 202190 (SB) inhibitor of p38 MAPK 10M 
RO 320432 (RO) inhibitor of PKC 1M 
4-DAMP methiodide (4-DAMP) M3 and M5 AChR antagonist 1nM – 100nM 
Methoctramine hemihydrate (Methoc) M2 AChR antagonist 10pM – 1nM 
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Table 2. Primer Sequences for QRT-PCR 
Gene of Interest Sequence (5’ to 3’) Size (bp) Annealing temp. 
(°C) 
GAPDH           (for)  
                         (rev) 
ACAGTCCATGCCATCACTGCC 
GCCTGCTTCACCACCTTCTTG 
320 55 
Muscarinic (M) AChR    
M1                    (for)  
                          (rev) 
CCGACTAAGAAAGGGCGTGA 
GCAGCAGGCGAAAGGTGT 
313 57 
M2                    (for)  
                          (rev) 
ACAAGAAGGAGCCTGTTGCCAACC 
CAATCTTGCGGGCTACAATATTCTG 
438 57 
M3                    (for)  
                          (rev) 
GACAGAAAACTTTGTCCACCCCAC 
AGAAGTCTTAGCTGTGTCCACGGC 
496 62 
M4                    (for)  
                          (rev) 
TCCTCAAGAGCCCACTAATGAAGC 
TTCTTGCGCACCTGGTTGCGAGC 
430 59 
M5                    (for)  
(rev) 
CTCACCACCTGTAGCAGCTACCC 
CTCTCTTTCGTTTGGTCATTTGATG 
397 59 
COL1A2           (for)  
                          (rev) 
ATATTGCACCTTTGGACATC 
TGCTCTGATCAATCCTTCTT 
236 55 
TGF- β              (for)  
                          (rev) 
AACCCACAACGAAATCTATG 
GTGCTGCTCCACTTTTAACT 
157 55 
ASMA              (for)  
                          (rev) 
ACC CAC AAT GTC CCC ATC TA 
TGA TCC ACA TCT GCT GGA AG 
300 55 
 
